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Abstract
Complement is an essential component of the innate and acquired immune system1, and consists
of a series of proteolytic cascades that are initiated by the presence of micro-organisms. In health,
activation of complement is precisely controlled through membrane-bound and soluble plasma-
regulatory proteins including factor H (fH)2, a 155 kDa protein composed of twenty domains
(termed complement control protein repeats, or CCPs). Many pathogens have evolved the ability
to avoid immune- killing by recruiting host complement regulators3 and several pathogens have
adapted to avoid complement-mediated killing by sequestering fH to their surface4. Here we
present the first structure of a complement regulator in complex with its pathogen surface-protein
ligand. This reveals how the important human pathogen Neisseria meningitidis subverts immune
responses by mimicking the host, using protein instead of charged-carbohydrate chemistry to
recruit the host complement regulator, factor H. The structure also indicates the molecular basis of
the host-specificity of the interaction between factor H and the meningococcus, and informs
attempts to develop novel therapeutics and vaccines.
Neisseria meningitidis is a human adapted pathogen of global importance as a leading cause
of bacterial meningitis and septic shock5. Due to Neisserial strain variation, the vaccines
currently available for meningococcal disease are only effective against subsets of strains
and do not provide universal protection6,7. However, promising novel antigens have been
identified8, including factor H binding protein (known as fHbp, GNA1870, or R2086), a 27
kDa surface lipoprotein which is present on the surface of all strains of N. meningitidis and
elicits protective bactericidal antibodies9,10. The structure of a portion of fHbp has been
determined by NMR11, and its function studied by subdividing it into a series of regions,
termed “A”, “B” and “C” 12. fHbp is the sole receptor for fH on the meningococcus, and
recruitment of fH contributes to the ability of the meningococcus to avoid innate immune
responses by inhibiting complement-mediated lysis in human plasma13,14. Individuals with
polymorphisms in the promoter of the gene encoding fH that are associated with increased
plasma fH levels are at increased risk from meningococcal disease15.
Correspondence and requests for materials should be addressed to S.M.L. (susan.lea@path.ox.ac.uk) or C.M.T.
(c.tang@imperial.ac.uk)..
*These authors contributed equally to this work
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Coordinates and X-ray data have been deposited in the protein databank with accession identifiers 2w80 & 2w81.
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We have used a range of approaches to dissect the fH binding sites on fHbp (Fig. 1). High
affinity interactions between fH and fHbp were only observed with fHbp constructs
containing all three of the previously defined (see above) regions of fHbp (Fig. 1a),
implying that fHbp has an extended recognition site for fH across its entire surface. We then
sought to identify which of the 20 CCP domains of fH mediate the interaction with fHbp.
Far Western, FACS (Fig. 1b) and Surface Plasmon Resonance (Fig. 1c) analyses
demonstrated that the key regions of fH recognised by fHbp are the sixth and seventh
domains, CCPs 6 & 7 (known hereafter as fH67) and that a construct containing both these
domains was capable of inhibiting the fHbp-dependent interaction between fH and N.
meningitidis (Fig. 1d). Quantification of the interaction demonstrates that the dissociation
constant is ~5nM (Fig. 1c & 1e, Tab. S1, Fig. S1) for any construct containing CCPs 6 & 7.
This interaction was not dissociated by high salt (1M NaCl, not shown) or pH ranging from
4 to 8 (not shown), providing additional support for the high affinity nature of the binding
event.
To better understand fH:fHbp recognition, we crystallised and determined crystal structures
of the complex between fH67 and an fHbp construct comprising regions A, B and C but
lacking the lipid anchor. Models for fHbp and fH67 were built and refined to 2.35 Å in two
crystal forms with a total of seven independent copies of the complex (Fig. 2). The structure
reveals that fHbp folds to form two ß–barrels (Fig. 2a) with the N-terminal barrel consisting
of the “A” and part of the “B” regions, whilst the C-terminal barrel (as previously seen in
the NMR structure of the “BC” region11, overlaid in Fig. S2) is composed of the rest of the
“B” and the “C” regions. Searching structural databases with the N-terminal barrel reveals
no close structural homologues (Supplemental Analyses), and the distinct topologies of the
ß-barrels (Fig. 2c) suggest that they have not arisen by a gene duplication event.
The fH67:fHbp complex is held together by extensive interactions between both ß-barrels of
fHbp and fH CCP6 (Fig. 2b), with more minor contacts to CCP7, consistent with our
binding studies. In particular, the helical insertion into the second ß-strand of CCP6 (an
unusual feature of this CCP domain) is centrally located in the complex. Analysis by the
PISA server gives all seven independent complexes a significance score of 1.0 (i.e.
extremely likely to be biologically significant) with the average surface area of fHbp buried
in the complex (2860±177Å2) greater than that buried in most antibody:antigen
complexes16. Furthermore, the ΔG predicted on the basis of the structure for the formation
of the complex (−6 kcal/mol) is in good agreement with the affinity derived from binding
studies (−11 kcal/mol, calculated from KD presented in Fig. 1e), providing additional
support for the physiological relevance of the crystallised complex. The interaction surface
shows good shape complementarity with numerous electrostatic interactions (Fig. 2c, Fig.
S3) including multiple hydrogen bonds and salt bridges. To further probe the interaction
surface we generated doubly mutated forms of both proteins with charged side chains being
replaced by the small hydrophobic residue Ala (fH67R341A,H337A and fHbpE283A,E304A).
Using SPR to study the interactions between the mutated proteins and their wild-type
partners revealed that the affinity of both mutant forms was reduced by more than two
orders of magnitude so that almost no interaction could be seen at analyte concentrations
(~50 nM) around ten times the wild-type KD (Fig. 3a). At a thousand-fold higher analyte
concentration (μM range) the mutant forms of both proteins did interact with the wild-type
partners: fHbpE283A,E304A retained a qualitatively similar on-rate but an increased off-rate
with respect to wild-type, whilst fH67R341A,H337A was more similar to the wild-type
interaction in its off-rate but had a vastly reduced on-rate (Tab. S1). It is interesting to note
that E304 is not conserved in all Neisserial strains with a Thr also found at this position10.
Since these strains also sequester fH it is likely that either the loss of a single interaction
(rather than the two lost in the mutant) does not decrease the affinity sufficiently to preclude
functional fH sequestration or that subtle rearrangements of the local side chains allow the
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Thr side chain to interact with residues in fH. The ability of the interaction to tolerate some
variation in the residues at the interface would clearly be immunologically advantageous.
A common fH polymorphism (fH 402His/Tyr), recently shown to be a major susceptibility
factor for age related macular degeneration17-19, lies at the periphery of the interaction site
and the side chain of residue 402 (His in this structure) is within hydrogen bonding distance
of residues in fHbp (Fig. S4 & S5). However, our interaction studies do not detect any
differences in binding (Fig. 1e, Tab. S1) between the fH 402His/Tyr isoforms. This lack of
functional consequence suggests, as for variation at the 304 position (see above) that either
the loss of a single hydrogen bond from this extensive interaction surface is not sufficient to
produce a functional effect or that the small amount of flexibility at the CCP 6/7 junction
seen between the crystallographically independent copies of the complex allows subtle
rearrangement of the fH CCP domains to enable both polymorphic variants to hydrogen
bond to fHbp (Fig. S4).
Mapping published epitopes of fHbp that elicit bactericidal antibodies11,12 onto the
structure demonstrates that none of the sites characterised to date lie directly in the fH
recognition site. Instead, epitopes recognised by antibodies that affect fH binding20 are
located around the edge of the recognition site and so are likely to inhibit fH binding by
steric hindrance (Fig. S5).
Our earlier structure21 of CCPs 6, 7 & 8 of fH in complex with sucrose octasulphate (SOS),
a highly sulphated analogue of glycosaminoglycans (GAGs), revealed a charged groove on
fH that forms an extended interaction site for binding of GAGs on the surface of endothelial
cells. This, combined with an additional GAG-binding site in CCPs 19-2022, provides the
mechanism by which fH localises to mammalian cells23 to prevent inappropriate
complement activation. Examination of the fHbp:fH67 complex demonstrates that the
Neisserial protein binding site lies within this extended GAG interaction site, overlapping
the CCP6 SOS-binding site (Fig. 3b) with no fH rearrangement upon binding fHbp (Fig S6).
There are several examples of pathogens imitating their host by expressing directly related
molecules (e.g. sialic acid or glycolipids24). Here, however, N. meningitidis mimics the
mechanism by which host cells regulate complement activation on their surface using amino
acid side-chains instead of charged sugars. Since the binding sites of fHbp and SOS on fH
are overlapping, we tested whether SOS can act as a competitive inhibitor of the interaction
between fH and fHbp. Strikingly, SOS prevented the fH/fHbp interaction (assessed by SPR
Fig. 3d, and by FACS Fig. S7) at millimolar concentrations, supporting the relevance of the
crystal structure to complex formation in solution and providing a lead compound for
development of small molecule inhibitors of fH:fHbp interactions.
N. meningitidis has evolved to avoid innate responses at sites of colonisation and during
disease. It is also host-restricted, with the human nasopharynx its only natural reservoir5.
This host specificity can limit the significance of animal models for studying certain aspects
of pathogenesis and immunity. It has previously been shown that N. meningitidis only binds
human fH and not fH from other primates or other animals25. The amino acid sequences of
fH from human and other primates are highly conserved (~90% identity) whilst other animal
fHs are more sequence divergent. It is therefore of note that even the limited number of
differences between human and primate sequence changes within CCP6 cluster to the
precise site of interaction with fHbp. For instance, mapping the differences between human
and rhesus macaque fH26 shows that all six differences within CCP6 lie in or around the
interface (Fig. 3e). This indicates the likely structural basis for the species specificity of
complement evasion25 by N. meningitidis through fH recruitment, and suggests that specific
modification of fH could provide a novel approach to develop more biologically relevant
models of meningococcal disease.
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Interestingly, the high affinity interaction between fH and fHbp suggests that N.
meningitidis could rapidly sequester fH in the plasma, depleting the circulating levels and
de-regulating complement, rendering host cells in the vascular compartment more
susceptible to complement-mediated damage. This might contribute to the dramatic
haemorrhagic rash seen in meningococcal sepsis, and suggests that inhibitors specifically
designed to block the interaction between CCP6 and fHbp might both promote complement-
mediated clearance of bacteria and prevent sequestration of fH and consequent vascular
damage27.
The success of meningococcal vaccines containing fHbp which are currently being
evaluated may be hampered by binding of fH which, due to high affinity and the extensive
sites of interaction, could cloak critical, conserved epitopes on the antigen. Structural
analysis of this complex paves the way for the development of engineered fHbp vaccines in
which fH binding is abolished to unveil the full array of protective epitopes including those
that could generate responses to inhibit recruitment of fH by this important human pathogen.
Summary Methods
Full methods are described in the supplementary material. Recombinant proteins were
expressed and purified using affinity columns or size exclusion chromatography and protein
concentration estimated using absorbance at λ=280nm. Binding assays (FACS, far Western
and SPR) were performed according to published protocols. The complex was crystallised
by vapour diffusion and X-ray diffraction data collected at the European Synchrotron
Radiation Facility (ESRF, France) and DIAMOND (UK). The structure was solved by a
combination of molecular replacement for the fH67 portion21 (1/3 of the structure) and
isomorphous replacement/anomalous dispersion methods, with seven independent copies
refined to 2.35Å in two different crystal forms.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. The fHbp binding site is localised to CCP6 of fH and requires the complete
extracellular portion of fHbp
(a) Far Western analysis of fH binding to intact fHbp and truncated versions (as indicated).
Membranes were incubated with purified fH which was detected with α-fH pAbs. Binding
was only observed to the intact 27 kDa fHbp (shown with an arrow). (b) FACS analysis with
α-fH pAbs detected binding between N. meningitidis and fH constructs (all of the His form)
containing CCPs 6 & 7 (note that where binding is seen the relative magnitude of the
response is not significant since the amount of pAb bound is approximately proportional to
the size of the fH construct rather than the tightness of the binding event) and (c) SPR
demonstrates that fHbp is only able to bind fH constructs containing CCPs 6 and 7 (the
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number of molecules of the fH fragments coupled on the sensor channels is in the ratio
1:1:1:3 for fh78:fh567:fh678:fh67, respectively). Signals shown are after subtraction of a
control trace from a mock-coupled channel. With the experiment reversed the inset shows a
1:1 Langmuir fit (black lines) to a series of fH678 dilutions (coloured lines) injected over a
fHbp surface to determine kinetic parameters (Fig. 1e & Tab. S1). (d) FACS competition
studies (using an α-fH mAb directed against CCP5 (MRC OX2428) and therefore unable to
recognize the fH67 construct) show that the short fH67 construct (between 0.3 and 33 μM)
can compete away binding of full length fH demonstrating that this construct contains the
entire fHbp binding site. Values shown are percentage of fluorescence positive cells in a
population from three experiments ± s.d. The gate value was set using a control with no fH
added. (e) Quantitation with SPR confirms that the presence of CCPs 6 and 7 is necessary
and sufficient for high affinity binding to fHbp and that the common fH polymorphism in
CCP7 (402His/Tyr) does not significantly alter the affinity of fHbp binding.
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Figure 2. Structure of fHbp and its complex with fH67
(a) Two views of a cartoon representation of fHbp (residues 80 to 320). The cartoon is
coloured according to the regions previously used to study fHbp (“A” region yellow, “B”
region green, “C” region cyan) illustrating the way in which these constructs do not reflect
the overall architecture. (b) Cartoon of the fHbp:fH67 complex with fHbp coloured as in (a)
and fh67 in dark blue. Side chains from both proteins involved in forming salt bridges across
the interaction surface are shown in red as ball-and-stick representations (zoomed and
reoriented in inset box). (c) Topology of fHbp and fh67 coloured as in (b) with the number
of the residues involved in either H-bond or salt-bridge interactions between the proteins
highlighted in red. The numbering scheme used throughout is as per Uniprot sequence
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Q9JXV4. This scheme is offset by +164 from the numbering used for the earlier NMR
structure11 (which was numbered from the start of their fragment) and by −65 from the
scheme used in Masignani et al.10 where numbering started from residue 1 of the mature
protein without the signal sequence.
Schneider et al. Page 10
Nature. Author manuscript; available in PMC 2009 October 16.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Figure 3. Interference with fHbp binding of fH
(a) Site-directed mutagenesis to use Ala to substitute charged side-chains, shown by the
structure to be involved in complex-formation, abolishes binding to the wild-type form of
their partner at concentrations around the wild-type KD. The black bar indicates the time
period for which the fH analytes were injected (at 50 nM, 40 μl.min−1) over the fHbp
surfaces.(b) Overlay of the fH-bound SOS (in gold as ball-and-stick and semi-transparent
surface) from the structure of fH678 in complex with SOS21 onto our fHbp:fH67 structure
(coloured as in 2b). This demonstrates that the sites of SOS and fHbp binding overlap,
suggesting that SOS could inhibit the interaction. (c) Mimicry of GAG binding to fH via
sulphate interactions (LH panel, SOS – green carbons, fH – grey carbons) by charged side
Schneider et al. Page 11
Nature. Author manuscript; available in PMC 2009 October 16.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
chain (Glu 304) of fHbp (RH panel, fHbp – cyan carbons, fH – grey carbons). (d) SPR
demonstrates that SOS inhibits binding of fHbp to fH in the mM concentration range (fH678
injected at 4nM, 40μl/min in presence of varying amounts of SOS) Values +/− one SD, n=3.
(e) Mapping of sites of amino acid differences in CCP6 of fH between human (UniProt
P08603) and rhesus macaque (UniProt O19279). Residues which are altered shown in pink,
space filling representation, with fHbp and fh67 shown as in panel (2b).
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